Synthesis and Characterization of Cefotaxime Conjugated Gold Nanoparticles and Their Use to Target Drug-Resistant CTX-M-Producing Bacterial Pathogens

Journal of Cellular Biochemistry

Volumn 118, Issue 9, 2017, Pages 2802-2808

  Shaikh, Sibhghatulla ^a   Rizvi, Syed Mohd Danish ^b   Shakil, Shazi ^c   Hussain, Talib ^b   Alshammari, Thamir M ^b,d   Ahmad, Waseem ^c   Tabrez, Shams ^c   Al Qahtani, Mohammad H ^c   Abuzenadah, Adel M ^c  

^a INTEGRAL UNIVERSITY   (India)

^b UNIVERSITY OF HAIL   (Saudi Arabia)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

CEFOTAXIME; CTX M; ESBL; GOLD NANOPARTICLES; MULTI DRUG RESISTANCE

Indexed keywords

BETA LACTAMASE CTX M; BROMELAIN; CEFOTAXIME; GOLD NANOPARTICLE; GOLD; METAL NANOPARTICLE;

AGAR DIFFUSION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TARGETING; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; SCANNING TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING;

CEFOTAXIME; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; GOLD; KLEBSIELLA PNEUMONIAE; METAL NANOPARTICLES;

EID: 85018723829     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25929     Document Type: Article

References (34)

1. Azam A, Ahmed AS, Oves M, Khan MS, Habib SS, Memic A. 2012. Antimicrobial activity of metal oxide nanoparticles against Gram-positive and Gram-negative bacteria: A comparative study. Int J Nanomedicine 7:6003–6009.
2. Berne BJ, Pecora R. 2000. Dynamic light scattering: With applications to chemistry, biology and physics. New York: Dover Publications Inc.
3. Bindu D, Mythili C, Mythili S, Inthira KS, Palanisamy R, Lingesh KT, Bindu TS. 2015. New generation of silver nanoparticles against extended spectrum beta lactamase producing organisms. Int J Drug Dev Res 7:3.
4. Bonnet R. 2004. Growing group of extended-spectrum beta-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 48:1–14.
5. Brown AN, Smith K, Samuels TA, Lu J, Obare SO, Scott ME. 2012. Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and methicillin-resistant Staphylococcus aureus. Appl Environ Microbiol 78:2768–2774.
6. Chu B. 1991. Laser light scattering: Basic principles and practice, 2nd Edition. Boston: Academic Press p 343.
7. Cobley CM, Chen J, Cho EC, Wang LV, Xia Y. 2011. Gold nanostructures: A class of multifunctional materials for biomedical applications. Chem Soc Rev 40:44–56.
8. Eckert C, Gautier V, Arlet G. 2006. DNA sequence analysis of the genetic environment of various blaCTX-M genes. J Antimicrob Chemother 57:14–23.
9. Eloff JN. 1998. A sensitive and quick micro plate method to determine the minimal inhibitory concentration of plant extracts for bacteria. Planta Medica 64:711–713.
10. Fako VE, Furgeson DY. 2009. Zebrafish as a correlative and predictive model for assessing biomaterial nanotoxicity. Adv Drug Deliv Rev 61:478–486.
11. Gomes MJ, Martins S, Ferreira D, Segundo MA, Reis S. 2014. Lipid nanoparticles for topical and transdermal application for alopecia treatment: Development, physicochemical characterization, and in vitro release and penetration studies. Int J Nanomedicine 9:1231–1242.
12. Grzybowski BA, Huck WT. 2016. The nanotechnology of life-inspired systems. Nat Nanotechnol 11:585–592.
13. Harris PNA, Tambyah PA, Paterson DL. 2015. Β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: Time for a reappraisal in the era of few antibiotic options. Lancet Infect Dis 15:475–485.
14. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson D. 2009. Emergence of high levels of extended spectrum b-lactamase-producing Gram negative bacilli in Asia/Pacific: Data from SMART 2007. Antimicrob Agents Chemother 53:3280–3284.
15. Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA. 2012. Nanotechnology-based approaches in anticancer research. Int J Nanomed 7:4391–4408.
16. Jamil B, Habib H, Abbasi SA, Ihsan A, Nasir H, Imran M. 2016. Development of cefotaxime impregnated chitosan as nano-antibiotics: De novo strategy to combat biofilm forming multi-drug resistant pathogens. Front Microbiol 7:330.
17. Khan S, Rizvi SMD, Avaish M, Arshad M, Bagga P, Khan MS. 2015a. A novel process for size controlled biosynthesis of gold nanoparticles using bromelain. Mater Lett 159:373–376.
18. Khan S, Haseeb M, Baig MH, Bagga PS, Siddiqui HH, Kamal MA, Khan MS. 2015b. Improved efficiency and stability of secnidazole—An ideal delivery system. Saudi J Biol Sci 22:42–49.
19. Majzik A, Patakfalvi R, Hornok V, Dékány I. 2009. Growing and stability of gold nanoparticles and their functionalization by cysteine. Gold Bull 42:113.
20. Mangeney C, Ferrage F, Aujard I, Marchi-Artzner V, Jullien L, Ouari O, Rekai ED, Laschewsky A, Vikholm I, Sadowski JW. 2002. Synthesis and properties of water-soluble gold colloids covalently derivatized with neutral polymer monolayers. J Am Chem Soc 124:5811–5821.
21. Marra AR, Pereira CAP, Castelo A, de Carmo Fihlo JR, Cal RGR, Sader HS, Wey SB. 2006. Health and economic outcomes of detection of Klebsiella pneumoniae produced extended-spectrum B-lactamase (ESBL) in a hospital with high prevalence of this infection. Int Infect Dis 10:56–60.
22. Mukherjee P, Bhattacharya R, Mukhopadhyay D. 2005. Gold nanoparticles bearing functional anti cancer drug and anti-angiogenic agent: A “2 in 1” system with potential application in cancer therapeutics. J Biomed Nanotech 2:2224–2228.
23. Nicolau DP. 2008. Carbapenems: A potent class of antibiotics. Expert Opin Pharmacother 9:23–37.
24. Perez C, Pauli M, Bazerque P. 1990. An antibiotic assay by the well agar method. Acta Biol Med Exp 15:113–115.
25. Rai A, Prabhune A, Perry CC. 2010. Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings. J Mater Chem 20:6789–6798.
26. Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, Pascual A. 2004. Epidemiology and clinical features of infections caused by extended spectrum beta-lactamase-producing Escherichia coli in non hospitalized patients. J Clin Microbiol 42:1089–1094.
27. Rossolini GM, Andrea MM, Mugnaiolic C. 2008. The spread of CTX-M type extended spectrum b-lactamases. Clin Microbiol Infect 14:33–41.
28. Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. 2015. Risk factors for acquisition of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae in a North-Indian hospital. Saudi J Biol Sci 22:37–41.
29. Shaikh S, Shakil S, Rizvi SMD, Roberts PM, Mushtaq G, Kamal MA. 2015a. Nanobiotechnological approaches against multidrug resistant bacterial pathogens: An update. Curr Drug Metab 16:362–370.
30. Shaikh S, Rizvi SMD, Anis R, Shakil S. 2016b. Prevalence of CTX-M resistance marker and integrons among Escherichia coli and Klebsiella pneumoniae isolates of clinical origin. Lett Appl Microbiol 62:419–427.
31. Shan C, Li F, Yuan F, Yang G, Niu L, Zhang Q. 2008. Size-controlled synthesis of monodispersed gold nanoparticles stabilized by polyelectrolyte-functionalized ionic liquid. Nanotechnology 19:285601.
32. Sultan A, Khan HM, Malik A, Ansari MA, Azam A, Perween N. 2015. Antibacterial activity of ZnO nanoparticles against ESBL and Amp-C producing Gram negative isolates from superficial wound infections. Int J Curr Microbiol App Sci 1:38–47.
33. Timkovich R. 1977. Detection of the stable addition of carbodiimide to proteins. Anal Biochem 20:138–143.
34. Tom RT, Suryanarayanan V, Reddy PG, Baskaran S, Pradeep T. 2004. Ciprofloxacin-protected gold nanoparticles. Langmuir 20:1909–1914.